PMC:4310921 / 6005-7879 JSONTXT

{"project":"NEUROSES","denotations":[{"id":"T272","span":{"begin":565,"end":576},"obj":"CHEBI_8871"},{"id":"T273","span":{"begin":795,"end":806},"obj":"CHEBI_8871"},{"id":"T274","span":{"begin":1245,"end":1256},"obj":"CHEBI_8871"},{"id":"T275","span":{"begin":1538,"end":1549},"obj":"CHEBI_8871"},{"id":"T276","span":{"begin":659,"end":668},"obj":"CHEBI_350546"},{"id":"T277","span":{"begin":659,"end":668},"obj":"CHEBI_28790"},{"id":"T278","span":{"begin":678,"end":688},"obj":"CHEBI_35222"},{"id":"T279","span":{"begin":717,"end":731},"obj":"CHEBI_22720"},{"id":"T280","span":{"begin":739,"end":754},"obj":"CHEBI_6887"},{"id":"T281","span":{"begin":766,"end":777},"obj":"CHEBI_3048"},{"id":"T282","span":{"begin":873,"end":882},"obj":"CHEBI_81580"},{"id":"T283","span":{"begin":1057,"end":1066},"obj":"CHEBI_81580"},{"id":"T284","span":{"begin":1291,"end":1300},"obj":"CHEBI_81580"},{"id":"T285","span":{"begin":1364,"end":1373},"obj":"CHEBI_81580"},{"id":"T286","span":{"begin":1626,"end":1635},"obj":"CHEBI_81580"},{"id":"T287","span":{"begin":1777,"end":1786},"obj":"CHEBI_81580"},{"id":"T288","span":{"begin":947,"end":953},"obj":"PATO_0000461"},{"id":"T289","span":{"begin":995,"end":999},"obj":"PATO_0000384"},{"id":"T290","span":{"begin":995,"end":999},"obj":"CHEBI_30780"},{"id":"T291","span":{"begin":1015,"end":1021},"obj":"PATO_0000383"},{"id":"T292","span":{"begin":1327,"end":1330},"obj":"PATO_0000011"},{"id":"T293","span":{"begin":1408,"end":1411},"obj":"PATO_0000011"},{"id":"T294","span":{"begin":1832,"end":1835},"obj":"PATO_0000011"},{"id":"T295","span":{"begin":1327,"end":1330},"obj":"CHEBI_84123"},{"id":"T296","span":{"begin":1408,"end":1411},"obj":"CHEBI_84123"},{"id":"T297","span":{"begin":1832,"end":1835},"obj":"CHEBI_84123"},{"id":"T298","span":{"begin":1374,"end":1383},"obj":"PATO_0001687"},{"id":"T299","span":{"begin":1418,"end":1425},"obj":"CHEBI_4167"},{"id":"T300","span":{"begin":1418,"end":1425},"obj":"CHEBI_42758"},{"id":"T301","span":{"begin":1418,"end":1425},"obj":"CHEBI_17234"},{"id":"T302","span":{"begin":1462,"end":1467},"obj":"CHEBI_18059"},{"id":"T303","span":{"begin":1494,"end":1497},"obj":"CHEBI_39025"},{"id":"T304","span":{"begin":1660,"end":1663},"obj":"CHEBI_39025"},{"id":"T305","span":{"begin":1708,"end":1711},"obj":"CHEBI_39025"},{"id":"T306","span":{"begin":1498,"end":1503},"obj":"PATO_0001038"},{"id":"T307","span":{"begin":1664,"end":1669},"obj":"PATO_0001038"},{"id":"T308","span":{"begin":1712,"end":1717},"obj":"PATO_0001038"},{"id":"T309","span":{"begin":1498,"end":1503},"obj":"PATO_0001470"},{"id":"T310","span":{"begin":1664,"end":1669},"obj":"PATO_0001470"},{"id":"T311","span":{"begin":1712,"end":1717},"obj":"PATO_0001470"},{"id":"T312","span":{"begin":1613,"end":1621},"obj":"PATO_0001727"},{"id":"T313","span":{"begin":1613,"end":1621},"obj":"PATO_0002360"},{"id":"T314","span":{"begin":1736,"end":1741},"obj":"CHEBI_24433"},{"id":"T315","span":{"begin":1772,"end":1776},"obj":"PATO_0000469"},{"id":"T316","span":{"begin":237,"end":247},"obj":"PM3425"},{"id":"T317","span":{"begin":416,"end":426},"obj":"PM3425"},{"id":"T318","span":{"begin":237,"end":247},"obj":"PM3425"},{"id":"T319","span":{"begin":416,"end":426},"obj":"PM3425"}],"text":"RESULTS\nIn total, 25 patients (aged 12.1±3.3 years, 19 boys and 6 girls) were enrolled in the study. The results are listed in Table 1 and summarized in Table 2 and 3. Most of the patients were diagnosed with ADHD, a tic disorder, major depression, bipolar disorder, disruptive behavior disorder, psychotic disorder, or mental retardation. The most common diagnoses were tic disorder (n=10, 40%) and mood disorders (depression and bipolar disorder; n=11, 44%), while six patients (24%) had an anxiety disorder and six (24%) had ADHD.\nTen subjects (40%) were taking risperidone monotherapy. Among the remainder, the concomitant medications comprised selective serotonin reuptake inhibitors (36%), valproic acid (20%), benzodiazepine (16%), methylphenidate (12%), and benztropine (8%).\nThe median risperidone dosage was 1.55 mg/day (SD=1.14 mg/day, range 0.25-4 mg/day). The prolactin level (33.65±16.71 ng/mL, range 5.8-68.3 ng/mL) was higher than normal, with hyperprolactinemia (\u003e15.2 ng/mL in male, \u003e23.3ng/mL in female) found in 84% of the patients. The prolactin level was higher than 30 and 50 ng/mL in 15 (60%) and 4 (16%) of these patients, respectively. None of the children presented clinical signs of hyperprolactinemia.\nThe dosage of risperidone was significantly correlated with prolactin level after adjusting for age and BMI (p\u003c0.001, r=0.813). This prolactin elevation was not correlated with age, sex, glucose, thyroid hormones, sex hormones, or lipid profiles. However, the TG/HDL ratio was significantly associated with risperidone dosage (r=0.570, p=0.004) (Figure 1). In addition, there was a tendency for prolactin to increase with the TG/HDL ratio (r=0.391, p=0.059) (Figure 2).\nThe TG/HDL ratio was higher in the group of patients with particularly high prolactin levels (i.e., ≥30 ng/mL) after adjusting for age and BMI (p=0.028) (Figure 3, Table 4)."}